By Siddhi Mahatole Feb 17 (Reuters) - Disc Medicine said on Tuesday it will pursue a traditional U.S. approval pathway for ...

Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in ...

The U.S. Food and Drug Administration (FDA) has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), to ...

Novocure NVCR recently announced the FDA approval for its portable therapeutic device, Optune Pax, for treating adult ...

Medtronic’s Infuse bone graft earned the FDA’s premarket approval for one- and two-level transforaminal lumbar interbody spinal fusions. The expanded approval allows use with PEEK and titanium ...

The FDA has approved a new, simplified monthly subcutaneous (SC) dosing schedule for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; Johnson & Johnson) for the treatment of patients with ...

The company said Tuesday that the FDA greenlit a supplemental new drug application for Wakix, a treatment for cataplexy, a narcolepsy symptom characterized by sudden muscle weakness, in pediatric ...

The Stealth AXiS system architecture allows support for a variety of surgeon preferences and clinical complexities.

FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...

PHOENIX, AZ - February 02, 2026 - PRESSADVANTAGE - Phoenix NP, a women-focused telehealth medical practice based in ...

Optune Pax is a portable medical device that delivers TTFields non-invasively via wearable arrays to disrupt electrical processes essential for cancer cell division.

The approvals stem from the Phase III KEYNOTE-B96 trial data, which was presented at the 2025 ESMO Congress.